Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga· 3 days agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Merck KGaA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 6 days agoMerck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29. As investors...
Is Merck Stock Fully Valued At $130?
Forbes· 4 days agoMerck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The growth was primarily driven by higher sales...
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 6 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report released on Friday, Benzinga reports ...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 6 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Cerevance receives milestone payment under Alzheimer's collaboration with Merck
Seeking Alpha· 3 days agoPrivately held Cerevance receives milestone payment from Merck for Alzheimer's research...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 4 days agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck reports data from Phase III gastric cancer treatment trial
Clinical Trials Arena via Yahoo Finance· 3 days agoMerck (MSD) has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial...
Michael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks By Investing.com
Investing.com· 2 days agoMichael Burgess trades in AbbVie, IBM, iShares ETF, and Merck stocks